T Cell Recognition of Autoantigens in Human Type 1 Diabetes: Clinical Perspectives

Type 1 diabetes (T1D) is an autoimmune disease driven by the activation of lymphocytes against pancreatic β-cells. Among β-cell autoantigens, preproinsulin has been ascribed a key role in the T1D process. The successive steps that control the activation of autoreactive lymphocytes have been extensiv...

Full description

Bibliographic Details
Main Authors: Roberto Mallone, Vedran Brezar, Christian Boitard
Format: Article
Language:English
Published: Hindawi Limited 2011-01-01
Series:Clinical and Developmental Immunology
Online Access:http://dx.doi.org/10.1155/2011/513210
id doaj-f479fd34b50d484b9207c1b9b63a0072
record_format Article
spelling doaj-f479fd34b50d484b9207c1b9b63a00722020-11-25T00:59:15ZengHindawi LimitedClinical and Developmental Immunology1740-25221740-25302011-01-01201110.1155/2011/513210513210T Cell Recognition of Autoantigens in Human Type 1 Diabetes: Clinical PerspectivesRoberto Mallone0Vedran Brezar1Christian Boitard2INSERM, U986, Hôpital St Vincent de Paul, 82 avenue Denfert Rochereau, 75014 Paris, FranceINSERM, U986, Hôpital St Vincent de Paul, 82 avenue Denfert Rochereau, 75014 Paris, FranceINSERM, U986, Hôpital St Vincent de Paul, 82 avenue Denfert Rochereau, 75014 Paris, FranceType 1 diabetes (T1D) is an autoimmune disease driven by the activation of lymphocytes against pancreatic β-cells. Among β-cell autoantigens, preproinsulin has been ascribed a key role in the T1D process. The successive steps that control the activation of autoreactive lymphocytes have been extensively studied in animal models of T1D, but remains ill defined in man. In man, T lymphocytes, especially CD8+ T cells, are predominant within insulitis. Developing T-cell assays in diabetes autoimmunity is, thus, a major challenge. It is expected to help defining autoantigens and epitopes that drive the disease process, to pinpoint key functional features of epitope-specific T lymphocytes along the natural history of diabetes and to pave the way towards therapeutic strategies to induce immune tolerance to β-cells. New T-cell technologies will allow defining autoreactive T-cell differentiation programs and characterizing autoimmune responses in comparison with physiologically appropriate immune responses. This may prove instrumental in the discovery of immune correlates of efficacy in clinical trials.http://dx.doi.org/10.1155/2011/513210
collection DOAJ
language English
format Article
sources DOAJ
author Roberto Mallone
Vedran Brezar
Christian Boitard
spellingShingle Roberto Mallone
Vedran Brezar
Christian Boitard
T Cell Recognition of Autoantigens in Human Type 1 Diabetes: Clinical Perspectives
Clinical and Developmental Immunology
author_facet Roberto Mallone
Vedran Brezar
Christian Boitard
author_sort Roberto Mallone
title T Cell Recognition of Autoantigens in Human Type 1 Diabetes: Clinical Perspectives
title_short T Cell Recognition of Autoantigens in Human Type 1 Diabetes: Clinical Perspectives
title_full T Cell Recognition of Autoantigens in Human Type 1 Diabetes: Clinical Perspectives
title_fullStr T Cell Recognition of Autoantigens in Human Type 1 Diabetes: Clinical Perspectives
title_full_unstemmed T Cell Recognition of Autoantigens in Human Type 1 Diabetes: Clinical Perspectives
title_sort t cell recognition of autoantigens in human type 1 diabetes: clinical perspectives
publisher Hindawi Limited
series Clinical and Developmental Immunology
issn 1740-2522
1740-2530
publishDate 2011-01-01
description Type 1 diabetes (T1D) is an autoimmune disease driven by the activation of lymphocytes against pancreatic β-cells. Among β-cell autoantigens, preproinsulin has been ascribed a key role in the T1D process. The successive steps that control the activation of autoreactive lymphocytes have been extensively studied in animal models of T1D, but remains ill defined in man. In man, T lymphocytes, especially CD8+ T cells, are predominant within insulitis. Developing T-cell assays in diabetes autoimmunity is, thus, a major challenge. It is expected to help defining autoantigens and epitopes that drive the disease process, to pinpoint key functional features of epitope-specific T lymphocytes along the natural history of diabetes and to pave the way towards therapeutic strategies to induce immune tolerance to β-cells. New T-cell technologies will allow defining autoreactive T-cell differentiation programs and characterizing autoimmune responses in comparison with physiologically appropriate immune responses. This may prove instrumental in the discovery of immune correlates of efficacy in clinical trials.
url http://dx.doi.org/10.1155/2011/513210
work_keys_str_mv AT robertomallone tcellrecognitionofautoantigensinhumantype1diabetesclinicalperspectives
AT vedranbrezar tcellrecognitionofautoantigensinhumantype1diabetesclinicalperspectives
AT christianboitard tcellrecognitionofautoantigensinhumantype1diabetesclinicalperspectives
_version_ 1725218353801330688